---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-066061"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2026-06-08T12:45:18+00:00"
generated_at: "2026-06-08T12:50:37.339815+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Federal Circuit upholds CorMedix's MINOCIN patents; Nexus generic barred from market

## Summary
- Federal Circuit affirmed district court: Nexus generic minocycline infringes two CorMedix patents, invalidity rejected.
- Permanent injunction upheld barring Nexus from marketing generic before patent expiration.
- Patents are FDA Orange Book listed covering MINOCIN for Injection, used for serious infections.
- CEO Joseph Todisco: ruling validates strength of MINOCIN IP portfolio and protects innovation.

## SEC filing metadata
- accession: 0001213900-26-066061
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2026-06-08T12:45:18+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390026066061/0001213900-26-066061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390026066061/ea0293895-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-066061
- JSON: https://secwatch.observer/filing/0001213900-26-066061.json
- Plain text: https://secwatch.observer/filing/0001213900-26-066061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.